全文获取类型
收费全文 | 4792篇 |
免费 | 367篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 189篇 |
妇产科学 | 7篇 |
基础医学 | 274篇 |
口腔科学 | 17篇 |
临床医学 | 154篇 |
内科学 | 3394篇 |
皮肤病学 | 64篇 |
神经病学 | 30篇 |
特种医学 | 22篇 |
外科学 | 31篇 |
综合类 | 77篇 |
预防医学 | 53篇 |
眼科学 | 14篇 |
药学 | 158篇 |
中国医学 | 11篇 |
肿瘤学 | 680篇 |
出版年
2023年 | 90篇 |
2022年 | 24篇 |
2021年 | 54篇 |
2020年 | 138篇 |
2019年 | 133篇 |
2018年 | 123篇 |
2017年 | 127篇 |
2016年 | 153篇 |
2015年 | 152篇 |
2014年 | 185篇 |
2013年 | 243篇 |
2012年 | 154篇 |
2011年 | 192篇 |
2010年 | 178篇 |
2009年 | 192篇 |
2008年 | 187篇 |
2007年 | 210篇 |
2006年 | 160篇 |
2005年 | 170篇 |
2004年 | 147篇 |
2003年 | 170篇 |
2002年 | 181篇 |
2001年 | 167篇 |
2000年 | 173篇 |
1999年 | 119篇 |
1998年 | 116篇 |
1997年 | 136篇 |
1996年 | 143篇 |
1995年 | 138篇 |
1994年 | 106篇 |
1993年 | 43篇 |
1992年 | 44篇 |
1991年 | 46篇 |
1990年 | 35篇 |
1989年 | 33篇 |
1988年 | 36篇 |
1987年 | 36篇 |
1986年 | 20篇 |
1985年 | 80篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 37篇 |
1981年 | 46篇 |
1980年 | 32篇 |
1979年 | 42篇 |
1978年 | 37篇 |
1977年 | 31篇 |
1976年 | 19篇 |
1975年 | 17篇 |
1971年 | 4篇 |
排序方式: 共有5177条查询结果,搜索用时 31 毫秒
91.
92.
B. Douglas Smith Barbara J. Bambach Milada S. Vala James P. Barber Cheryl Enger Robert A. Brodsky Philip J. Burke Steven D. Gore & Richard J. Jones 《British journal of haematology》1998,102(4):1042-1049
Despite extensive investigation into mechanisms of drug resistance in acute myeloid leukaemia (AML), the aetiology of therapeutic resistance is unclear. We found that five leukaemia cell lines (K562, HL-60, CEM, CEM induced to overexpress bcl-2, and REH) displayed parallel sensitivity to four antileukaemia drugs with different mechanisms of action, with K562 generally being the least sensitive and REH being the most sensitive. The amount of spontaneous apoptosis in the cell lines after serum-free culture paralleled their drug sensitivity: K562 cells displayed the least apoptosis at 24 h (2.50 ± 0.24%) and REH the most (24.47 ± 8.22%). The extent of spontaneous apoptosis of leukaemic blasts from 39 patients with newly diagnosed de novo AML also correlated with the success of the intensive, infusional cytarabine-based induction therapy. There was a median of 19.5% (range 3.6–64%) apoptotic AML cells after 24 h of serum-free culture in patients who entered a complete remission compared with 4.2% (1.8–7.0%) apoptotic AML cells in patients who did not achieve a complete remission ( P = 0.0007). Thus, inhibited apoptosis was associated with both in vitro and in vivo pan-resistance to antileukaemic chemotherapy. The cause of inhibited apoptosis in AML is probably a function of interactions among multiple signals that influence apoptosis. Assessment of spontaneous apoptosis may serve as an important prognostic factor for AML. 相似文献
93.
Weintraub M Kaplinsky C Amariglio N Rosner E Brok-Simoni F Rechavi G 《British journal of haematology》2000,111(2):641-643
Congenital leukaemia (CL) is a rare disorder that presents with extramedullary infiltrates and a myeloid phenotype. CL can progress rapidly without adequate treatment, but, paradoxically, may also remit spontaneously. Because of the significant toxicity involved in delivering chemotherapy to newborns, it is important to identify those newborns who may not require treatment. We describe an infant who presented at 1 week of age with congenital myeloid leukaemia. Cytogenetic analysis revealed a t(8;16)(q11;p13) translocation. The infant's leukaemia underwent a spontaneous regression. This case further confirms the possibility of spontaneous remission in congenital leukaemia. Moreover, it suggests that the presence of a clonal cytogenetic aberration does not preclude the possibility of a spontaneous regression in CL. 相似文献
94.
95.
Korkolopoulou P Gribabis DA Kavantzas N Angelopoulou MK Siakantaris MP Patsouris E Androulaki A Thymara I Kokoris SI Kyrtsonis MC Kittas C Pangalis GA 《British journal of haematology》2003,122(6):900-910
Bone marrow angiogenesis has recently been implicated in the pathophysiology and course of various haematological malignancies. Little is known, however, about the significance of this phenomenon in hairy cell leukaemia (HCL). We evaluated various morphometric characteristics of microvessels, highlighted by means of anti-CD34 immunohistochemistry, in the bone marrow of 44 patients with typical HCL, before and after treatment with interferon-alpha (IFN-alpha). Overall, bone marrow from 103 HCL patients and 20 controls was examined. Microvessel density (MVD) and several size- and shape-related parameters were quantified in the region of most intense vascularization using image analysis. MVD, size-related parameters and the percentage of branching microvessels were higher in HCL than in controls. Likewise, perimeter counts were higher in partial/non-responders than in complete responders. Achievement of complete response was accompanied by smaller calibre microvessels. IFN-alpha induced a decrease in MVD and branching values in cases with diffuse marrow involvement. In univariate analysis, progression-free survival was adversely affected by MVD, branching and major axis length. Multivariate analysis indicated that MVD/branching independently affected progression-free survival and the likelihood of complete response. Our data suggest that the generation of bone marrow microvessels indicated an increased risk of progression and IFN-alpha treatment failure in HCL. Furthermore, the prognostic significance of angiogenesis requires the concomitant assessment of MVD and the complexity of the microvascular network. 相似文献
96.
Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia 总被引:1,自引:0,他引:1
M. J. Brisco P. J. Sykes E. Hughes G. Dolman S-H. Neoh L-M. Peng I. Toogood & A. A. Morley 《British journal of haematology》1997,99(2):314-319
The use of peripheral blood rather than marrow has potential advantages for monitoring minimal residual disease during the treatment of leukaemia. To determine the feasibility of using blood, we used a sensitive polymerase chain reaction method to quantify leukaemia in the blood and marrow in 35 paired samples from 15 children during induction treatment. Leukaemic cells in the blood ranged from 1.1 × 10−2 to < 9.4 × 10−7 leukaemic cells/total cells, corresponding to 1.3 × 107 to < 2 × 103 leukaemic cells/l. In 15 paired samples, leukaemia could be quantified in both tissues and in 20 paired samples, leukaemia was not detected in one or both tissues so that only upper level limits could be set. In the former 15 pairs, the level of leukaemia in peripheral blood was directly proportional to that in marrow but was a mean of 11.7-fold lower. Leukaemia in blood was detected in 10/12 pairs in which the level in marrow was > 10−4 , but in only two of 13 pairs in which the level in marrow was < 10−5 . Patients studied at multiple time-points showed parallel declines in the number of leukaemic cells in both tissues. The results showed that leukaemia could be monitored in peripheral blood during induction therapy, and quantitative considerations based on the results suggest that monitoring of blood during post-induction therapy may be of value in detecting molecular relapse. 相似文献
97.
Current risk-adjusted intensive therapies for childhood acute lymphoblastic leukaemia (ALL) are expected to result in an event-free survival of greater than 75%. In sharp contrast, relapsed paediatric ALL is a difficult disease to treat. In this study, 25 paediatric patients with ALL were analysed at diagnosis and relapse for their p16 (exon 2) status using the most accurate method of detection, real-time polymerase chain reaction (PCR). The median time to relapse for the group was 27 months. At diagnosis, the incidence of p16 homozygous and hemizygous deletion in this group was 32% and 20% respectively. The incidence of homozygous p16 deletion at relapse was 64%. A large number of patients, eight of 16 (50%), developed p16 homozygous deletion at relapse. Of those eight patients, four were hemizygous and four were germline at diagnosis. At diagnosis, those patients with a homozygous or hemizygous p16 deletion relapsed sooner than those germline for p16. We have shown that p16 alterations are frequently present in relapsed lymphoblastic leukaemia in children. 相似文献
98.
Anders Waage Daniel Remick Sigurd Steinshamn Laura Deforge Jon Lamvik 《British journal of haematology》1994,86(1):36-40
Serum levels of interleukin 8 (IL-8) were examined in eight patients with acute myeloid leukaemia during 16 courses of chemotherapy. The patients experienced 14 episodes of fever which occurred in periods with granulocyte counts <0·5 × 109 /l. Febrile episodes were classified as bacteriologically defined infection ( n = 6), clinically defined infection ( n = 2), and unexplained fever ( n = 6). IL-8 was detected in 18/25 (72%), 2/3 (67%) and 3/7 (43%) of the serum samples in the respective groups. In contrast, IL-8 was detected in 22/90 (24%) of the samples taken when no fever was present ( P <0·00003 versus bacteriologically defined infection). The median concentration of IL-8 in samples taken during febrile episodes was 194 ng/ml (range 0–6358 ng/ml) and 0 (range 0–5392 ng/ml) on days without fever (not significant). In three patients with infections caused by, respectively, Streptococcus sanguis, Acinetobacter calcoanitratus and Candida albicans , IL-8 rose to a peak levels and declined during recovery. We conclude that IL-I is released systemically during infections with gram-positive and gram-negative bacteria and Candida albicans in patients with acute myeloid leukaemia and peripheral granulocytopenia due to chemotherapy. However, IL-8 can also be detected when no sign of infection is present. 相似文献
99.
Wright AM Paterson AR Sowa B Akabutu JJ Grundy PE Gati WP 《British journal of haematology》2002,116(3):528-537
2-chlorodeoxyadenosine (2-CdA) and arabinosylcytosine (araC) are nucleoside drugs that are used to treat various leukaemias, although 2-CdA has not been tested extensively in children with acute lymphoblastic leukaemia (ALL). Nucleoside cytotoxicity depends on the conversion of these agents to 5'-phosphate derivatives, following drug entry into cells via nucleoside transport (NT) processes. This study compared es nucleoside transporter content, determined using a flow cytometric assay with SAENTA [5'-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5'-thioadenosine] fluorescein, and cytotoxicities of 2-CdA and araC in fresh lymphoblasts from previously untreated paediatric ALL patients and the human T-lymphoblast cell line, CCRF-CEM. Lymphoblast samples from individual patients ranged widely in sensitivity to both 2-CdA (IC50, 6 nmol/l to > 5 micromol/l; mean = 418 nmol/l; n = 8) and araC (IC50, 59 nmol/l to > 5 micromol/l; mean = 1050 nmol/l; n = 7), although IC50 values for the two drugs were correlated (r = 0.78, P = 0.032, n = 7). Cellular es nucleoside transporter content varied more than 35-fold among samples from 10 patients. The correlation between es nucleoside transporter content and drug sensitivity was statistically significant for araC (r = -0.93, P = 0.023, n = 5), but not for 2-CdA (r = -0.57, P = 0.23, n = 6). Exposure of CCRF-CEM cells to araC resulted in a substantial araC concentration-dependent increase in the relative survival of es transporter-deficient cells, whereas the increase was slight following exposure to 2-CdA. We conclude that, in ALL lymphoblasts, es nucleoside transporter content is a determinant of araC sensitivity and that a deficiency in NT may impart resistance to araC. 相似文献
100.
Barrett AJ 《British journal of haematology》2008,142(6):877-888
The graft-versus-leukaemia (GVL) effect is a central component of the stem cell allograft's ability to cure haematological malignancies. The GVL effect is mediated by donor-derived natural killer cells and T lymphocytes, which have distinct mechanisms of recognizing and targeting the recipient's malignant cells. After transplantation the cytokine milieu is favourable to the early establishment of a GVL effect, but the need to prevent graft-versus-host disease limits the full potential of this process. Clinical studies have identified some critical components of the transplant preparation, donor selection, stem cell source (peripheral blood versus bone marrow) and post-transplant management that can be manipulated to optimize the GVL effect. However, further developments focusing on the selective depletion of unwanted alloreactivity with preservation of GVL effects, and the use of vaccines or the adoptive transfer of leukaemia-specific lymphocytes, will be required to enhance the GVL effect to reliably eradicate more resistant leukaemias. 相似文献